CADM4

Summary

CADM4 (cell adhesion molecule 4, HGNC:30825) is a protein-coding gene on chromosome 19q13.31, encoding Cell adhesion molecule 4 (Q8NFZ8). Involved in the cell-cell adhesion. It is a selective cancer dependency (DepMap: 10.8% of cell lines).

Enables vascular endothelial growth factor receptor 2 binding activity. Involved in several processes, including negative regulation of protein phosphorylation; regulation of Rac protein signal transduction; and regulation of wound healing. Located in cell leading edge and cell-cell contact zone.

Source: NCBI Gene 199731 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 56 total
• Cancer dependency (DepMap): dependent in 10.8% of screened cell lines
• MANE Select transcript: NM_145296

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30825
Approved symbol	CADM4
Name	cell adhesion molecule 4
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	TSLL2, Necl-4, SynCAM4
Ensembl gene	ENSG00000105767
Ensembl biotype	protein_coding
OMIM	609744
Entrez	199731

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000222374, ENST00000593506, ENST00000904152, ENST00000904153, ENST00000904154, ENST00000904155, ENST00000904156, ENST00000904157

RefSeq mRNA: 1 — MANE Select: NM_145296 NM_145296

CCDS: CCDS12627

Canonical transcript exons

ENST00000222374 — 9 exons

Exon	Start	End
ENSE00000710805	43624114	43624242
ENSE00000710809	43625911	43626001
ENSE00000710810	43626124	43626288
ENSE00000710812	43626784	43626918
ENSE00000710813	43627166	43627318
ENSE00000847433	43627644	43627790
ENSE00001212252	43622368	43623439
ENSE00001212255	43639727	43639850
ENSE00003550743	43625078	43625250

Expression profiles

Bgee: expression breadth ubiquitous, 218 present calls, max score 98.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.4042 / max 271.3708, expressed in 988 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181302	7.6248	982
181303	0.4966	105
181304	0.2828	84

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.69	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.65	gold quality
nerve	UBERON:0001021	97.86	gold quality
tibial nerve	UBERON:0001323	97.86	gold quality
ganglionic eminence	UBERON:0004023	97.78	gold quality
ventricular zone	UBERON:0003053	97.20	gold quality
right frontal lobe	UBERON:0002810	96.90	gold quality
spinal cord	UBERON:0002240	96.89	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.69	gold quality
nucleus accumbens	UBERON:0001882	96.62	gold quality
amygdala	UBERON:0001876	96.47	gold quality
cerebellar hemisphere	UBERON:0002245	96.31	gold quality
cerebellar cortex	UBERON:0002129	96.16	gold quality
sural nerve	UBERON:0015488	95.82	gold quality
prefrontal cortex	UBERON:0000451	95.78	gold quality
caudate nucleus	UBERON:0001873	95.61	gold quality
putamen	UBERON:0001874	95.50	gold quality
cingulate cortex	UBERON:0003027	94.36	gold quality
anterior cingulate cortex	UBERON:0009835	94.25	gold quality
adenohypophysis	UBERON:0002196	94.07	gold quality
cerebellum	UBERON:0002037	94.00	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.00	gold quality
ventral tegmental area	UBERON:0002691	93.85	gold quality
pons	UBERON:0000988	92.97	gold quality
pituitary gland	UBERON:0000007	92.96	gold quality
inferior vagus X ganglion	UBERON:0005363	92.71	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.66	gold quality
subthalamic nucleus	UBERON:0001906	92.45	gold quality
neocortex	UBERON:0001950	92.34	gold quality
telencephalon	UBERON:0001893	92.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

74 targeting CADM4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 11)

• TSLL2 is expressed at the cell-cell attachment sites in the renal tubules, the transitional epithelia of the bladder, and the glandular epithelia of the prostate, and is a tumor-suppressor candidate in prostate cancer. (PMID:16261159)
• Nec- 4 suppress the growth and tumorigenic ability of colon cancer cells. (PMID:19565570)
• CADM4, as well as 4.1B is expressed specifically in human proximal tubules. (PMID:21544807)
• Loss or decrease of CADM4 expression seems to play an important role in breast cancer invasiveness, and it is associated with poorer biological parameters. (PMID:23559354)
• results indicate that Necl-4 serves as a tumor suppressor by inhibiting the ErbB2/ErbB3 signaling and hemidesmosome disassembly (PMID:23611113)
• Cadm4 regulates the growth of the myelin unit and the organization of the underlying axonal membrane. (PMID:23825401)
• Necl-4 serves as a novel regulator for contact inhibition of cell movement and proliferation cooperatively with the VEGF receptor and PTPN13 (PMID:25893857)
• There was a significant association between RNase 5 and histological differentiation in colon adenocarcinomas, but no association between RNase 5 and Necl 4 in gastric or colon adenocarcinomas (PMID:28561015)
• The results suggest that Necl-4 enhances VEGF-induced activation of PLCgamma-c-Raf-MEK-ERK pathway without affecting the phosphorylation and internalization of VEGFR2. (PMID:28601637)
• Low CADM4 expression is associated with bone marrow metastasis in neuroblastoma. (PMID:28921546)
• Cell adhesion molecule 4 suppresses cell growth and metastasis by inhibiting the Akt signaling pathway in non-small cell lung cancer. (PMID:32325280)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cadm4	ENSDARG00000040291
mus_musculus	Cadm4	ENSMUSG00000054793
rattus_norvegicus	Cadm4	ENSRNOG00000024243
drosophila_melanogaster	Fas3	FBGN0000636

Paralogs (14): PVR (ENSG00000073008), CD200 (ENSG00000091972), CRTAM (ENSG00000109943), NECTIN1 (ENSG00000110400), NECTIN2 (ENSG00000130202), NECTIN4 (ENSG00000143217), CD226 (ENSG00000150637), CADM3 (ENSG00000162706), SMAGP (ENSG00000170545), CADM2 (ENSG00000175161), NECTIN3 (ENSG00000177707), TIGIT (ENSG00000181847), CADM1 (ENSG00000182985), NCR3 (ENSG00000204475)

Protein

Protein identifiers

Cell adhesion molecule 4 — Q8NFZ8 (reviewed: Q8NFZ8)

Alternative names: Immunoglobulin superfamily member 4C, Nectin-like protein 4, TSLC1-like protein 2

All UniProt accessions (1): Q8NFZ8

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the cell-cell adhesion. Has calcium- and magnesium-independent cell-cell adhesion activity. May have tumor-suppressor activity.

Subunit / interactions. Monomer and homodimer.

Subcellular location. Membrane.

Tissue specificity. Expressed in brain, prostate, brain, kidney and some other organs.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the nectin family.

RefSeq proteins (1): NP_660339* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003585	Neurexin-like	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013162	CD80_C2-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF07686, PF08205, PF13927

UniProt features (16 total): glycosylation site 3, disulfide bond 3, domain 3, topological domain 2, signal peptide 1, chain 1, sequence variant 1, transmembrane region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFZ8-F1	85.31	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 361

Disulfide bonds (3): 44–104, 145–199, 245–291

Glycosylation sites (3): 67, 286, 31

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 188 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, MORF_ITGA2, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_NEGATIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION, BENPORATH_ES_WITH_H3K27ME3, GOBP_VASCULAR_ENDOTHELIAL_GROWTH_FACTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_REGULATION_OF_PHOSPHORYLATION, MORF_BRCA1, AAGCCAT_MIR135A_MIR135B, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_VASCULAR_ENDOTHELIAL_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, MORF_RAD51L3, GOBP_WOUND_HEALING

GO Biological Process (12): regulation of protein phosphorylation (GO:0001932), negative regulation of protein phosphorylation (GO:0001933), homophilic cell-cell adhesion (GO:0007156), negative regulation of peptidyl-threonine phosphorylation (GO:0010801), negative regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030948), regulation of Rac protein signal transduction (GO:0035020), regulation of cell population proliferation (GO:0042127), negative regulation of peptidyl-tyrosine phosphorylation (GO:0050732), regulation of wound healing (GO:0061041), negative regulation of vascular endothelial growth factor signaling pathway (GO:1900747), regulation of cell motility (GO:2000145), cell adhesion (GO:0007155)

GO Molecular Function (5): protein phosphatase binding (GO:0019903), receptor tyrosine kinase binding (GO:0030971), vascular endothelial growth factor receptor 1 binding (GO:0043183), vascular endothelial growth factor receptor 2 binding (GO:0043184), protein binding (GO:0005515)

GO Cellular Component (3): membrane (GO:0016020), cell leading edge (GO:0031252), cell-cell contact zone (GO:0044291)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein phosphorylation	2
negative regulation of protein phosphorylation	2
negative regulation of signal transduction	2
regulation of cellular process	2
vascular endothelial growth factor receptor binding	2
cellular anatomical structure	2
regulation of protein modification process	1
regulation of phosphorylation	1
regulation of protein phosphorylation	1
negative regulation of protein modification process	1
negative regulation of phosphorylation	1
cell-cell adhesion	1
regulation of peptidyl-threonine phosphorylation	1
peptidyl-threonine phosphorylation	1
regulation of vascular endothelial growth factor receptor signaling pathway	1
vascular endothelial growth factor receptor signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
Rac protein signal transduction	1
regulation of small GTPase mediated signal transduction	1
cell population proliferation	1
peptidyl-tyrosine phosphorylation	1
regulation of peptidyl-tyrosine phosphorylation	1
wound healing	1
regulation of response to wounding	1
vascular endothelial growth factor signaling pathway	1
regulation of vascular endothelial growth factor signaling pathway	1
negative regulation of cellular response to vascular endothelial growth factor stimulus	1
regulation of locomotion	1
cell motility	1
cellular process	1
phosphatase binding	1
signaling receptor binding	1
protein tyrosine kinase binding	1
binding	1
cell-cell junction	1

Protein interactions and networks

STRING

1040 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CADM4	PALS2	Q9NZW5	888
CADM4	CADM3	Q8N126	849
CADM4	EPB41L2	O43491	727
CADM4	EPB41	P11171	628
CADM4	CNTNAP1	P78357	593
CADM4	PTPN13	Q12923	578
CADM4	MPP3	Q13368	521
CADM4	NRG1	P98202	519
CADM4	DLG3	Q92796	499
CADM4	SLC44A1	Q8WWI5	474
CADM4	CADM2	Q8N3J6	462
CADM4	NFASC	O94856	454
CADM4	GLDN	Q6ZMI3	400
CADM4	CCN5	O76076	399
CADM4	AFDN	P55196	397

IntAct

56 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
EPHB6	FKBP5	psi-mi:“MI:0914”(association)	0.570
CD69	PALM3	psi-mi:“MI:0914”(association)	0.530
CLEC4A	SEMA7A	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
NCEH1	CLGN	psi-mi:“MI:0914”(association)	0.530
TSPAN16	CADM4	psi-mi:“MI:0915”(physical association)	0.500
CADM2	CADM4	psi-mi:“MI:0915”(physical association)	0.400
CADM3	CADM4	psi-mi:“MI:0915”(physical association)	0.400
SDK2	CADM4	psi-mi:“MI:0915”(physical association)	0.400
CSNK1E	CADM4	psi-mi:“MI:0915”(physical association)	0.370
CADM4	DYNC1I1	psi-mi:“MI:0915”(physical association)	0.370
CYP2S1	MPP2	psi-mi:“MI:0914”(association)	0.350
HEPACAM2	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
CD81	STX3	psi-mi:“MI:0914”(association)	0.350
CD81	PVR	psi-mi:“MI:0914”(association)	0.350
CD81	CD276	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
CERS2	VPS37C	psi-mi:“MI:0914”(association)	0.350
CLEC4A	RBFOX3	psi-mi:“MI:0914”(association)	0.350
HBG2	RAP1BL	psi-mi:“MI:0914”(association)	0.350
SCPEP1	CCDC85C	psi-mi:“MI:0914”(association)	0.350

BioGRID (57): CADM4 (Affinity Capture-RNA), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), CADM4 (Proximity Label-MS), CADM4 (Proximity Label-MS), CADM4 (Negative Genetic), CADM4 (Positive Genetic), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), CADM4 (Affinity Capture-MS), DIP2A (Affinity Capture-MS), CADM4 (Affinity Capture-MS)

ESM2 similar proteins: A0A5B9, A6NDV4, A6QLK4, B1AWJ5, E9PTA2, O75051, O94759, P01850, P01851, P01852, P01857, P01859, P01860, P01861, P01869, P01870, P01906, P01909, P03987, P06333, P0DSE2, P0DTU4, P11364, P15151, P15981, P20759, P20762, P32506, P54900, Q1WIM1, Q1WIM3, Q3TMX7, Q6P767, Q6ZRP7, Q7TQ33, Q812F8, Q8N126, Q8NFZ8, Q8R143, Q8R464

Diamond homologs: A0A0R4IGV4, P57087, P98160, Q05793, Q1WIM1, Q2WGK2, Q8NFZ8, Q8R464, Q925F2, Q9JI59, Q9XT56, Q9Y624, A0A087WV53, A1KZ92, A2AJ76, A4IFW2, A4IGL7, A6NDA9, B0BNK7, B0V2N1, D2HFT7, D3YXG0, D4A1J9, D4ABX8, F1NWE3, G5EG78, O15146, O73775, O75325, O94898, P07722, P15364, P20916, P20917, P23468, P43146, P48960, P53813, P70193, P70211

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1544 predictions. Top by Δscore:

Variant	Effect	Δscore
19:43623350:T:A	donor_gain	1.0000
19:43625072:TCTCA:T	donor_loss	1.0000
19:43625074:TCA:T	donor_loss	1.0000
19:43625075:CA:C	donor_loss	1.0000
19:43625076:A:AC	donor_gain	1.0000
19:43625077:C:CC	donor_gain	1.0000
19:43625246:TTGGC:T	acceptor_gain	1.0000
19:43625247:TGGC:T	acceptor_gain	1.0000
19:43625248:GGC:G	acceptor_gain	1.0000
19:43625249:GC:G	acceptor_gain	1.0000
19:43625250:CC:C	acceptor_gain	1.0000
19:43625251:C:CC	acceptor_gain	1.0000
19:43625251:C:T	acceptor_gain	1.0000
19:43625255:G:C	acceptor_gain	1.0000
19:43625255:G:GC	acceptor_gain	1.0000
19:43625261:A:AC	acceptor_gain	1.0000
19:43625261:A:C	acceptor_gain	1.0000
19:43626122:A:AC	donor_gain	1.0000
19:43626123:C:CC	donor_gain	1.0000
19:43626123:CA:C	donor_gain	1.0000
19:43626123:CACTG:C	donor_gain	1.0000
19:43626142:A:AC	donor_gain	1.0000
19:43626143:C:CC	donor_gain	1.0000
19:43626779:GGTAC:G	donor_loss	1.0000
19:43626914:GGCCA:G	acceptor_gain	1.0000
19:43626915:GCCA:G	acceptor_gain	1.0000
19:43626916:CCA:C	acceptor_gain	1.0000
19:43626916:CCAC:C	acceptor_gain	1.0000
19:43626917:CA:C	acceptor_gain	1.0000
19:43626917:CAC:C	acceptor_gain	1.0000

AlphaMissense

2493 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:43625232:C:A	W258C	1.000
19:43625232:C:G	W258C	1.000
19:43625233:C:G	W258S	1.000
19:43625234:A:G	W258R	1.000
19:43625234:A:T	W258R	1.000
19:43626809:C:A	W158C	1.000
19:43626809:C:G	W158C	1.000
19:43627219:C:G	C104S	1.000
19:43627220:A:G	C104R	1.000
19:43627220:A:T	C104S	1.000
19:43627237:T:A	D98V	1.000
19:43627237:T:G	D98A	1.000
19:43625121:A:C	N295K	0.999
19:43625121:A:T	N295K	0.999
19:43625134:C:G	C291S	0.999
19:43625135:A:G	C291R	0.999
19:43625135:A:T	C291S	0.999
19:43625141:A:C	Y289D	0.999
19:43625179:A:G	L276P	0.999
19:43625920:C:T	G249E	0.999
19:43625921:C:A	G249W	0.999
19:43625921:C:G	G249R	0.999
19:43625921:C:T	G249R	0.999
19:43625933:A:G	C245R	0.999
19:43625995:G:T	P224H	0.999
19:43626191:A:C	C199W	0.999
19:43626192:C:G	C199S	0.999
19:43626192:C:T	C199Y	0.999
19:43626193:A:G	C199R	0.999
19:43626193:A:T	C199S	0.999

dbSNP variants (sampled 300 via entrez): RS1000039450 (19:43625744 C>G), RS1000175877 (19:43639337 G>C), RS1000551131 (19:43632576 G>A,C), RS1000587602 (19:43624494 G>T), RS1000675266 (19:43638984 G>T), RS1000736845 (19:43631573 A>G), RS1000988281 (19:43638150 C>G), RS1000998533 (19:43623822 C>T), RS1001152694 (19:43631198 A>G), RS1001648252 (19:43632411 G>A,C), RS1001681705 (19:43627759 C>T), RS1001687965 (19:43639616 GC>G), RS1001732679 (19:43634699 G>A,T), RS1001771885 (19:43634349 C>T), RS1002066635 (19:43641844 G>A)

Disease associations

OMIM: gene MIM:609744 | disease phenotypes: MIM:602473

GenCC curated gene-disease

Mondo (1): ethylmalonic encephalopathy (MONDO:0011229)

Orphanet (1): Ethylmalonic encephalopathy (Orphanet:51188)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C535737	Ethylmalonic encephalopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, increases expression, affects cotreatment	6
trichostatin A	affects cotreatment, decreases expression, affects expression	4
entinostat	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression, affects cotreatment, increases abundance	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
pentanal	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation	1
Catechin	decreases expression, affects cotreatment	1
Estradiol	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
tert-Butylhydroperoxide	decreases expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00728481	PHASE2/PHASE3	COMPLETED	The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis